Table 10.
Five-Year Total, Annual Average Totala, and Average Annual Age-Adjusted Incidence Ratesb with 95% Confidence Intervals of All Brain and Other Central Nervous System Tumors by Histopathology, and NCI Age at Diagnosis Groups, CBTRUS Statistical Report: US Cancer Statistics – NPCR and SEER, 2015-2019
| Histopathology | Childrenc (0-14) | AYAd (15-39) | Older Adults (40+) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 5-Year Total | Annual Average | Rate (95% CI) | 5-Year Total | Annual Average | Rate (95% CI) | 5-Year Total | Annual Average | Rate (95% CI) | |
| Diffuse Astrocytic and Oligodendroglial Tumors | 1,410 | 282 | 0.47 (0.44-0.49) | 9,819 | 1,964 | 1.84 (1.80-1.87) | 72,783 | 14,557 | 8.72 (8.65-8.78) |
| Diffuse astrocytoma | 627 | 125 | 0.21 (0.19-0.22) | 2,614 | 523 | 0.48 (0.46-0.50) | 4,393 | 879 | 0.56 (0.54-0.58) |
| Anaplastic astrocytoma | 222 | 44 | 0.07 (0.06-0.08) | 2,046 | 409 | 0.38 (0.36-0.39) | 4,778 | 956 | 0.60 (0.58-0.62) |
| Glioblastoma | 465 | 93 | 0.15 (0.14-0.17) | 3,038 | 608 | 0.58 (0.56-0.60) | 59,755 | 11,951 | 7.03 (6.97-7.09) |
| Oligodendroglioma | 64 | 13 | 0.02 (0.02-0.03) | 1,426 | 285 | 0.27 (0.25-0.28) | 2,197 | 439 | 0.31 (0.29-0.32) |
| Anaplastic oligodendroglioma | -- | -- | -- | 517 | 103 | 0.10 (0.09-0.11) | 1,345 | 269 | 0.18 (0.17-0.19) |
| Oligoastrocytic tumors | -- | -- | -- | 178 | 36 | 0.03 (0.03-0.04) | 315 | 63 | 0.04 (0.04-0.05) |
| Other Astrocytic Tumors | 3,658 | 732 | 1.21 (1.17-1.24) | 1,836 | 367 | 0.34 (0.32-0.35) | 758 | 152 | 0.10 (0.10-0.11) |
| Pilocytic astrocytoma | 3,283 | 657 | 1.08 (1.04-1.12) | 1,463 | 293 | 0.27 (0.26-0.28) | 593 | 119 | 0.08 (0.07-0.09) |
| Unique astrocytoma variants | 375 | 75 | 0.12 (0.11-0.14) | 373 | 75 | 0.07 (0.06-0.08) | 165 | 33 | 0.02 (0.02-0.03) |
| Non-Malignant | 232 | 46 | 0.08 (0.07-0.09) | 112 | 22 | 0.02 (0.02-0.02) | 37 | 7 | 0.01 (0.00-0.01) |
| Malignant | 143 | 29 | 0.05 (0.04-0.06) | 261 | 52 | 0.05 (0.04-0.05) | 128 | 26 | 0.02 (0.01-0.02) |
| Ependymal Tumors | 925 | 185 | 0.30 (0.28-0.32) | 1,924 | 385 | 0.36 (0.34-0.38) | 4,062 | 812 | 0.53 (0.51-0.54) |
| Non-Malignant | 112 | 22 | 0.04 (0.03-0.04) | 910 | 182 | 0.17 (0.16-0.18) | 1,980 | 396 | 0.26 (0.25-0.27) |
| Malignant | 813 | 163 | 0.27 (0.25-0.29) | 1,014 | 203 | 0.19 (0.18-0.20) | 2,082 | 416 | 0.27 (0.26-0.28) |
| Other Gliomas | 2,690 | 538 | 0.89 (0.85-0.92) | 1,925 | 385 | 0.35 (0.34-0.37) | 4,239 | 848 | 0.53 (0.52-0.55) |
| Glioma malignant, NOS | 2,668 | 534 | 0.88 (0.85-0.91) | 1,889 | 378 | 0.35 (0.33-0.36) | 4,196 | 839 | 0.53 (0.51-0.54) |
| Other neuroepithelial tumors | 22 | 4 | 0.01 (0.00-0.01) | 36 | 7 | 0.01 (0.00-0.01) | 43 | 9 | 0.01 (0.00-0.01) |
| Non-Malignant | -- | -- | -- | -- | -- | -- | 26 | 5 | 0.00 (0.00-0.01) |
| Malignant | -- | -- | -- | -- | -- | -- | 17 | 3 | 0.00 (0.00-0.00) |
| Neuronal and Mixed Neuronal-Glial Tumors | 1,411 | 282 | 0.47 (0.44-0.49) | 2,164 | 433 | 0.40 (0.38-0.42) | 1,764 | 353 | 0.23 (0.22-0.24) |
| Non-Malignant | 1,324 | 265 | 0.44 (0.41-0.46) | 1,973 | 395 | 0.36 (0.35-0.38) | 1,082 | 216 | 0.15 (0.14-0.16) |
| Malignant | 87 | 17 | 0.03 (0.02-0.04) | 191 | 38 | 0.04 (0.03-0.04) | 682 | 136 | 0.09 (0.08-0.09) |
| Choroid Plexus Tumors | 359 | 72 | 0.12 (0.11-0.13) | 210 | 42 | 0.04 (0.03-0.04) | 258 | 52 | 0.03 (0.03-0.04) |
| Non-Malignant | 261 | 52 | 0.09 (0.08-0.10) | -- | -- | -- | -- | -- | -- |
| Malignant | 98 | 20 | 0.03 (0.03-0.04) | -- | -- | ---- | -- | -- | ---- |
| Tumors of the Pineal Region | 143 | 29 | 0.05 (0.04-0.06) | 294 | 59 | 0.05 (0.05-0.06) | 332 | 66 | 0.04 (0.04-0.05) |
| Non-Malignant | 18 | 4 | 0.01 (0.00-0.01) | 117 | 23 | 0.02 (0.02-0.03) | 172 | 34 | 0.02 (0.02-0.03) |
| Malignant | 125 | 25 | 0.04 (0.03-0.05) | 177 | 35 | 0.03 (0.03-0.04) | 160 | 32 | 0.02 (0.02-0.02) |
| Embryonal Tumors | 2,144 | 429 | 0.71 (0.68-0.74) | 755 | 151 | 0.14 (0.13-0.15) | 271 | 54 | 0.04 (0.03-0.04) |
| Medulloblastoma | 1,464 | 293 | 0.48 (0.46-0.51) | 633 | 127 | 0.11 (0.11-0.12) | 155 | 31 | 0.02 (0.02-0.03) |
| Atypical teratoid/rhabdoid tumor | 365 | 73 | 0.12 (0.11-0.13) | 31 | 6 | 0.01 (0.00-0.01) | 16 | 3 | 0.00 (0.00-0.00) |
| All other embryonal | 315 | 63 | 0.10 (0.09-0.12) | 91 | 18 | 0.02 (0.01-0.02) | 100 | 20 | 0.01 (0.01-0.02) |
| Tumors of Cranial and Paraspinal Nerves | 686 | 137 | 0.23 (0.21-0.24) | 5,518 | 1,104 | 1.05 (1.02-1.07) | 30,844 | 6,169 | 3.79 (3.75-3.83) |
| Nerve sheath tumors | -- | -- | -- | -- | -- | -- | 30,818 | 6,164 | 3.79 (3.74-3.83) |
| Non-Malignant | -- | -- | -- | -- | -- | -- | 30,671 | 6,134 | 3.77 (3.73-3.81) |
| Malignant | -- | -- | -- | -- | -- | -- | 147 | 29 | 0.02 (0.02-0.02) |
| Other tumors of cranial and paraspinal nerves | -- | -- | -- | -- | -- | -- | 26 | 5 | 0.00 (0.00-0.00) |
| Tumors of Meninges | 680 | 136 | 0.22 (0.21-0.24) | 11,756 | 2,351 | 2.27 (2.23-2.32) | 171,969 | 34,394 | 20.91 (20.81-21.01) |
| Meningiomas | -- | -- | -- | 10,127 | 2,025 | 1.97 (1.93-2.01) | 168,002 | 33,600 | 20.41 (20.31-20.51) |
| Non-Malignant | -- | -- | -- | 10,015 | 2,003 | 1.95 (1.91-1.99) | 166,514 | 33,303 | 20.23 (20.13-20.33) |
| Malignant | -- | -- | -- | 112 | 22 | 0.02 (0.02-0.03) | 1,488 | 298 | 0.18 (0.17-0.19) |
| Mesenchymal tumors | 354 | 71 | 0.12 (0.10-0.13) | -- | -- | -- | 3,855 | 771 | 0.49 (0.47-0.50) |
| Non-Malignant | 285 | 57 | 0.09 (0.08-0.11) | -- | -- | -- | 3,324 | 665 | 0.42 (0.41-0.43) |
| Malignant | 69 | 14 | 0.02 (0.02-0.03) | -- | -- | -- | 531 | 106 | 0.07 (0.06-0.07) |
| Primary melanocytic lesions | -- | -- | -- | -- | -- | -- | 112 | 22 | 0.01 (0.01-0.02) |
| Non-Malignant | -- | -- | -- | -- | -- | -- | 44 | 9 | 0.01 (0.00-0.01) |
| Malignant | -- | -- | -- | -- | -- | -- | 68 | 14 | 0.01 (0.01-0.01) |
| Lymphomas and Hematopoietic Neoplasms | 89 | 18 | 0.03 (0.02-0.04) | 535 | 107 | 0.10 (0.09-0.11) | 7,901 | 1,580 | 0.94 (0.92-0.96) |
| Lymphoma | -- | -- | -- | -- | -- | -- | 7,862 | 1,572 | 0.94 (0.92-0.96) |
| Other hematopoietic neoplasms | -- | -- | -- | -- | -- | -- | 39 | 8 | 0.00 (0.00-0.01) |
| Germ Cell Tumors | 581 | 116 | 0.19 (0.18-0.21) | 625 | 125 | 0.11 (0.10-0.12) | 74 | 15 | 0.01 (0.01-0.01) |
| Non-Malignant | 82 | 16 | 0.03 (0.02-0.03) | 45 | 9 | 0.01 (0.01-0.01) | 43 | 9 | 0.01 (0.00-0.01) |
| Malignant | 499 | 100 | 0.16 (0.15-0.18) | 580 | 116 | 0.11 (0.10-0.11) | 31 | 6 | 0.00 (0.00-0.01) |
| Tumors of Sellar Region | 1,774 | 355 | 0.59 (0.56-0.61) | 23,663 | 4,733 | 4.39 (4.34-4.45) | 54,559 | 10,912 | 6.98 (6.91-7.04) |
| Tumors of the pituitary | 1,115 | 223 | 0.37 (0.35-0.39) | 22,980 | 4,596 | 4.26 (4.21-4.32) | 52,768 | 10,554 | 6.75 (6.69-6.81) |
| Non-Malignant | -- | -- | -- | -- | -- | -- | 52,678 | 10,536 | 6.74 (6.68-6.80) |
| Malignant | -- | -- | -- | -- | -- | -- | 90 | 18 | 0.01 (0.01-0.01) |
| Craniopharyngioma | 659 | 132 | 0.22 (0.20-0.24) | 683 | 137 | 0.13 (0.12-0.14) | 1,791 | 358 | 0.23 (0.21-0.24) |
| Unclassified Tumors | 1,010 | 202 | 0.33 (0.31-0.35) | 2,788 | 558 | 0.52 (0.50-0.54) | 14,606 | 2,921 | 1.80 (1.77-1.83) |
| Hemangioma | 287 | 57 | 0.09 (0.08-0.11) | 1,158 | 232 | 0.22 (0.20-0.23) | 2,770 | 554 | 0.36 (0.34-0.37) |
| Neoplasm, unspecified | 571 | 114 | 0.19 (0.17-0.20) | 1,503 | 301 | 0.28 (0.27-0.30) | 11,573 | 2,315 | 1.41 (1.38-1.44) |
| Non-Malignant | 409 | 82 | 0.14 (0.12-0.15) | 1,151 | 230 | 0.21 (0.20-0.23) | 5,394 | 1,079 | 0.66 (0.65-0.68) |
| Malignant | 162 | 32 | 0.05 (0.05-0.06) | 352 | 70 | 0.07 (0.06-0.07) | 6,179 | 1,236 | 0.75 (0.73-0.76) |
| All other | 152 | 30 | 0.05 (0.04-0.06) | 127 | 25 | 0.02 (0.02-0.03) | 263 | 53 | 0.03 (0.03-0.04) |
| Non-Malignant | 120 | 24 | 0.04 (0.03-0.05) | -- | -- | -- | -- | -- | -- |
| Malignant | 32 | 6 | 0.01 (0.01-0.01) | -- | -- | -- | -- | -- | -- |
| TOTAL e | 17,560 | 3,512 | 5.79 (5.70-5.88) | 63,812 | 12,762 | 11.96 (11.87-12.06) | 364,420 | 72,884 | 44.65 (44.51-44.80) |
| Non-Malignant | 5,888 | 1,178 | 1.94 (1.89-1.99) | 46,363 | 9,273 | 8.71 (8.63-8.79) | 267,063 | 53,413 | 32.92 (32.79-33.05) |
| Malignant | 11,672 | 2,334 | 3.85 (3.78-3.92) | 17,449 | 3,490 | 3.25 (3.20-3.30) | 97,357 | 19,471 | 11.74 (11.66-11.81) |
aAnnual average cases are calculated by dividing the five-year total by five.
bRates are per 100,000 and are age-adjusted to the 2000 US standard population.
cChildren as defined by the National Cancer Institute, see: http://www.cancer.gov/researchandfunding/snapshots/pediatric.
dAdolescents and Young Adults (AYA), as defined by the National Cancer Institute, see: http://www.cancer.gov/cancertopics/aya.
eRefers to all brain tumors including histopathologies not presented in this table.
-- Counts and rates are not presented when fewer than 16 cases were reported for the specific category. The suppressed cases are included in the counts and rates for totals.
Abbreviations: AYA, Adolescents and Young Adults; CBTRUS, Central Brain Tumor Registry of the United States; NPCR, National Program of Cancer Registries; SEER, Surveillance, Epidemiology, and End Results Program; CI, confidence interval; NOS, not otherwise specified.